Arcturus Therapeutics Holdings Inc. (ARCT)
Automate Your Wheel Strategy on ARCT
With Tiblio's Option Bot, you can configure your own wheel strategy including ARCT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARCT
- Rev/Share 4.9866
- Book/Share 8.6236
- PB 1.7336
- Debt/Equity 0.1668
- CurrentRatio 5.6426
- ROIC -0.2242
- MktCap 405452970.0
- FreeCF/Share -3.2865
- PFCF -4.5512
- PE -5.9421
- Debt/Assets 0.1175
- DivYield 0
- ROE -0.2741
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ARCT | Scotiabank | -- | Sector Outperform | -- | $32 | May 28, 2025 |
| Initiation | ARCT | BTIG Research | -- | Buy | -- | $41 | Jan. 28, 2025 |
News
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
Published: June 30, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announces positive Phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate designed to replace the OTC enzyme and restore urea cycle activity preventing hyperammonemia cr.
Read More
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
Read More
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials WALTHAM, Mass. and SAN DIEGO , Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older.
Read More
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-.
Read More
About Arcturus Therapeutics Holdings Inc. (ARCT)
- IPO Date 2013-05-22
- Website https://arcturusrx.com
- Industry Biotechnology
- CEO Joseph E. Payne
- Employees 174